Sir David Lane | |
---|---|
Born | David Philip Lane 1 July 1952 [1] Wimbledon, London, England |
Alma mater | |
Known for | Discovery of p53 |
Awards | Paul Ehrlich and Ludwig Darmstaedter Prize (1998) |
Scientific career | |
Fields | immunology |
Institutions | |
Doctoral students | Sara Mole [2] |
Sir David Philip Lane (born 1 July 1952) is a British immunologist, molecular biologist and cancer researcher. He is currently working in the Department of Microbiology, Tumor and Cell Biology at the Karolinska Institute and is Chairman of Chugai Pharmabody. He is best known for the discovery of p53, one of the most important tumour suppressor genes. [3]
Lane attended The John Fisher School in Purley, South London. He completed his undergraduate and postgraduate degrees at University College, London where he studied auto-immunity under the supervision of Avrion Mitchison.
Lane carried out postdoctoral research first at the Imperial Cancer Research Fund (ICRF) in London with Lionel Crawford and then at the Cold Spring Harbor Laboratory in New York with Joseph Sambrook. On returning to the UK, Lane set up his own laboratory with Cancer Research Campaign (CRC) funding at Imperial College, London, then moving to the ICRF laboratories at Clare Hall before moving in 1990 to the University of Dundee to help establish the CRC laboratories there.
He has played an active part in UK science, sitting at various times on the scientific committee of the CRC, the Cell Board of the MRC, and on the council of the ICRF. He is dedicated to the successful translation of research for patient benefit and participated in the early discussions around the scientific benefits of the merger of ICRF and CRC, before serving as chief scientist to their successor, Cancer Research UK, until 2010.[ citation needed ]
Lane founded the Dundee-based Biotechnology company, Cyclacel Ltd and was the chief scientific officer from 1996 to 2004. From 2004 to 2007, he was the executive director of the Institute of Molecular & Cell Biology (IMCB) in Singapore.[ citation needed ]
Sir David was chief scientist of Singapore's Agency for Science, Technology and Research (A*STAR, Singapore). He is also professor of tumour suppressor biology at the Department of Microbiology, Tumor and Cell Biology at the Karolinska Institute, where he is heading a research group.
Lane has published more than 350 research articles that have been cited over 100,000 times and is internationally recognised for his original discovery of the p53 protein SV40 T antigen complex and for his many subsequent contributions to the p53 field. The p53 gene is the most frequently altered gene in human cancer with more than half of all cancers having mutant p53. He is co-author with Ed Harlow of the most successful practical guide to the use of immunochemical methods. The "Antibodies" manual has sold over 40,000 copies.[ citation needed ]
Lane is a member of the European Molecular Biology Organization (EMBO), and in 1996 was elected a Fellow of the Royal Society, the UK's premier Academy. He is also a Fellow of the Royal Society of Edinburgh, the Royal College of Pathologists, the Royal College of Surgeons of Edinburgh and a founder member of the Academy of Medical Sciences.
He has won many international prizes for his work including the Joseph Steiner Prize, the Meyenburg Prize (1995), the Yvette Mayent Prize, the Paul Ehrlich Prize and the Cancer Research UK Lifetime Achievement Prize (2012). [4] He has been awarded honorary degrees from the Universities of Toulouse, Birmingham, Aberdeen, Stirling, Abertay, Brno and Nottingham. He has also been recognized for his business acumen with the award of Emerging Entrepreneur of the year.
On 29 September 2016 The John Fisher School opened the Sir David Lane building. [5]
He was knighted for his contribution to cancer research in the New Year honours list in January 2000.
p53, also known as Tumor protein P53, cellular tumor antigen p53, or transformation-related protein 53 (TRP53) is a regulatory protein that is often mutated in human cancers. The p53 proteins are crucial in vertebrates, where they prevent cancer formation. As such, p53 has been described as "the guardian of the genome" because of its role in conserving stability by preventing genome mutation. Hence TP53 is classified as a tumor suppressor gene.
A tumor suppressor gene (TSG), or anti-oncogene, is a gene that regulates a cell during cell division and replication. If the cell grows uncontrollably, it will result in cancer. When a tumor suppressor gene is mutated, it results in a loss or reduction in its function. In combination with other genetic mutations, this could allow the cell to grow abnormally. The loss of function for these genes may be even more significant in the development of human cancers, compared to the activation of oncogenes.
An oncovirus or oncogenic virus is a virus that can cause cancer. This term originated from studies of acutely transforming retroviruses in the 1950–60s, when the term oncornaviruses was used to denote their RNA virus origin. With the letters RNA removed, it now refers to any virus with a DNA or RNA genome causing cancer and is synonymous with tumor virus or cancer virus. The vast majority of human and animal viruses do not cause cancer, probably because of longstanding co-evolution between the virus and its host. Oncoviruses have been important not only in epidemiology, but also in investigations of cell cycle control mechanisms such as the retinoblastoma protein.
The Cancer Research UK London Research Institute (LRI) was a biological research facility which conducted research into the basic biology of cancer.
Karen Heather Vousden is a British medical researcher. She is known for her work on the tumour suppressor protein, p53, and in particular her discovery of the important regulatory role of Mdm2, an attractive target for anti-cancer agents. From 2003 to 2016, she was the director of the Cancer Research UK Beatson Institute in Glasgow, UK, moving back to London in 2016 to take up the role of Chief Scientist at CRUK and Group Leader at the Francis Crick Institute.
Inhibitor of growth protein 1 is a protein that in humans is encoded by the ING1 gene.
Molecular oncology is an interdisciplinary medical specialty at the interface of medicinal chemistry and oncology that refers to the investigation of the chemistry of cancer and tumors at the molecular scale. Also the development and application of molecularly targeted therapies.
Sir Peter John Ratcliffe, FRS, FMedSci is a British physician-scientist who is trained as a nephrologist. He was a practising clinician at the John Radcliffe Hospital, Oxford and Nuffield Professor of Clinical Medicine and head of the Nuffield Department of Clinical Medicine at the University of Oxford from 2004 to 2016. He has been a Fellow of Magdalen College, Oxford since 2004. In 2016 he became Clinical Research Director at the Francis Crick Institute, retaining a position at Oxford as a member of the Ludwig Institute of Cancer Research and director of the Target Discovery Institute, University of Oxford.
Terence Howard Rabbitts FRS FMedSci is currently Professor of Molecular Immunology at the Institute of Cancer Research, London.
Ashok Venkitaraman is a British cancer researcher of Indian origin. He is the Director of the Cancer Science Institute of Singapore, a Distinguished Professor of Medicine at the National University of Singapore, and Program Director at A*STAR, Singapore. From 1998 to 2020, he was the inaugural holder of the Ursula Zoellner Professorship of Cancer Research at the University of Cambridge, a Professorial Fellow at Pembroke College, Cambridge, and from 2006 to 2019, was the Director of the Medical Research Council Cancer Unit.
Janet S Butel is the Chairman and Distinguished Service Professor in the molecular virology and microbiology department at Baylor College of Medicine. Her area of expertise is on polyomavirus pathogenesis of infections and disease. She has more than 120 publications on PubMed. She also has 6 publications in Nature, which is considered one of the most prestigious science journals. She is a member of 9 different organizations and has 13 honors and awards.
Luis F. Parada is a Colombian developmental biologist and neuroscientist who currently serves as Director of the Brain Tumor Center, Albert C. Foster Chair and American Cancer Society Research Professor at Memorial Sloan Kettering Cancer Center in New York City, New York.
Scott William Lowe is Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center. He is recognized for his research on the tumor suppressor gene, p53, which is mutated in nearly half of cancers.
Professor Carol L. Prives FRS is the Da Costa Professor of Biological Sciences at Columbia University. She is known for her work in the characterisation of p53, an important tumor suppressor protein frequently mutated in cancer.
The large tumor antigen is a protein encoded in the genomes of polyomaviruses, which are small double-stranded DNA viruses. LTag is expressed early in the infectious cycle and is essential for viral proliferation. Containing four well-conserved protein domains as well as several intrinsically disordered regions, LTag is a fairly large multifunctional protein; in most polyomaviruses, it ranges from around 600-800 amino acids in length. LTag has two primary functions, both related to replication of the viral genome: it unwinds the virus's DNA to prepare it for replication, and it interacts with proteins in the host cell to dysregulate the cell cycle so that the host's DNA replication machinery can be used to replicate the virus's genome. Some polyomavirus LTag proteins - most notably the well-studied SV40 large tumor antigen from the SV40 virus - are oncoproteins that can induce neoplastic transformation in the host cell.
Xin Lu is a Professor of Cancer Biology and Director of the Ludwig Institute for Cancer Research at the University of Oxford. She is known for her discovery of and research on the ASPP family of proteins.
Richard Malcolm Marais a British researcher who is Director of the Cancer Research UK (CRUK) Manchester Institute and Professor of Molecular Oncology at the University of Manchester.
Sir Richard Henry Treisman is a British scientist specialising in the molecular biology of cancer. Treisman is a director of research at the Francis Crick Institute in London.
Sara Elizabeth Mole Crowley is a Professor of Molecular Cell Biology and Provost's Envoy for Gender Equality at University College London and the Great Ormond Street Hospital. She works on diseases caused by genetic changes, in particular neurodegenerative diseases that impact children.
Ellen Birgit Lane is a scientific researcher and academic in the field of human biology. She is the Executive Director of the Institute of Medical Biology, A*STAR, in Singapore, and the Chief Scientist of the Skin Research Institute of Singapore. Her research concerns the function of the epithelial cytoskeleton and its importance in disease.